Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 92
Filtrar
1.
BMC Pregnancy Childbirth ; 23(1): 650, 2023 Sep 08.
Artículo en Inglés | MEDLINE | ID: mdl-37684576

RESUMEN

INTRODUCTION: Prelabour rupture of membranes at term affects approximately 10% of women during pregnancy, and it is often associated with a higher risk of infection than when the membranes are intact. In an attempt to control the risk of infection, two main approaches have been used most widely in clinical practice: induction of labour (IOL) soon after the rupture of membranes, also called active management (AM), and watchful waiting for the spontaneous onset of labour, also called expectant management (EM). In addition, previous studies have demonstrated that vaginal examinations increase the risk of chorioamnionitis. However, the effect of vaginal examinations in the context of prelabour rupture of membranes have not been researched to the same extent. METHODS: This systematic review analyses and critiques the latest research on the management of term prelabour rupture of membranes, including the effect of vaginal examinations during labour, with a focus on the outcomes of both normal birth, and chorioamnionitis. Due to its complexity, three research questions were identified using the PICO diagram, and subsequently, the results from these searches were combined. The systematic review aimed to identify randomised controlled trials (RCTs) and observational studies that compared active vs expectant management, included number of vaginal examinations and had chorioamnionitis and/or normal birth as outcomes. The following databases were used: MEDLINE, EMBASE, Maternity and Infant care, LILACS, CINAHL and the Cochrane Central Register of Controlled trials. Quality was assessed using a tool developed especifically for this study that included questions from CASP and the Cochrane risk of bias tool. Due to the high degree of heterogeneity meta-analysis was not deemed appropriate. Therefore, simple narrative analysis was carried out. RESULTS: Thirty-two studies met the inclusion criteria, of which 27 were RCTs and 5 observational studies. The overall quality of the studies wasn't high, 15 out of the 32 studies were deemed to be low quality and only 17 out of 32 studies were deemed to be of intermediate quality. The systematic review revealed that the management of term prelabour rupture of membranes continues to be controversial. Previous research has compared active management (Induction of labour shortly after the rupture of membrane) against expectant management (watchful waiting for the spontaneous onset of labour). Although previous studies have demonstrated that vaginal examinations increase the risk of chorioamnionitis, no prospective studies have included an intervention to reduce the number of vaginal examinations. CONCLUSION: A RCT assessing the consequences of active management and expectant management as well as the effect of vaginal examinations during labour for term prelabour rupture of membranes is necessary.


Asunto(s)
Corioamnionitis , Trabajo de Parto , Femenino , Embarazo , Lactante , Niño , Humanos , Corioamnionitis/terapia , Parto Obstétrico , Bases de Datos Factuales , Cuidado del Lactante
2.
Pediatr Res ; 91(2): 289-296, 2022 01.
Artículo en Inglés | MEDLINE | ID: mdl-34211129

RESUMEN

Chorioamnionitis or intrauterine inflammation is a frequent cause of preterm birth. Chorioamnionitis can affect almost every organ of the developing fetus. Multiple microbes have been implicated to cause chorioamnionitis, but "sterile" inflammation appears to be more common. Eradication of microorganisms has not been shown to prevent the morbidity and mortality associated with chorioamnionitis as inflammatory mediators account for continued fetal and maternal injury. Mounting evidence now supports the concept that the ensuing neonatal immune dysfunction reflects the effects of inflammation on immune programming during critical developmental windows, leading to chronic inflammatory disorders as well as vulnerability to infection after birth. A better understanding of microbiome alterations and inflammatory dysregulation may help develop better treatment strategies for infants born to mothers with chorioamnionitis.


Asunto(s)
Corioamnionitis/fisiopatología , Corioamnionitis/inmunología , Corioamnionitis/microbiología , Corioamnionitis/terapia , Citocinas/metabolismo , Femenino , Humanos , Recién Nacido , Masculino , Embarazo , Resultado del Embarazo , Nacimiento Prematuro
3.
Obstet Gynecol Surv ; 76(2): 114-121, 2021 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-33625521

RESUMEN

IMPORTANCE: Intra-amniotic infection (IAI) is a common condition with potentially devastating maternal and neonatal complications. However, there are incomplete data regarding the most effective antimicrobial treatment regimen for this condition. OBJECTIVE: This article aims to review the current evidence and recommendations for intrapartum and postpartum management of IAI. EVIDENCE ACQUISITION: Original research articles, review articles, and guidelines on IAI were reviewed. RESULTS: Numerous known risk factors for IAI exist, some of which are modifiable. Serious neonatal complications can result from exposure to IAI including increased risk of preterm birth and neonatal death. Possible maternal complications include increased risk of cesarean delivery, postpartum hemorrhage, and postpartum endometritis. Antibiotics are the mainstay of treatment for IAI for both mothers and neonates, although there is no consensus on which antimicrobial agents are best and the appropriate duration of therapy. CONCLUSIONS AND RELEVANCE: Monitoring patients for signs of IAI, proper treatment, and communication of the diagnosis with the pediatric team are essential for preventing maternal and neonatal complications of IAI. More research is needed to determine the proper treatment regimens for both mothers diagnosed with IAI and their neonates.


Asunto(s)
Antibacterianos/uso terapéutico , Corioamnionitis/terapia , Atención Perinatal/métodos , Complicaciones Infecciosas del Embarazo/terapia , Atención Prenatal/métodos , Antibacterianos/normas , Femenino , Humanos , Recién Nacido , Atención Perinatal/normas , Guías de Práctica Clínica como Asunto , Embarazo , Nacimiento Prematuro/microbiología , Nacimiento Prematuro/prevención & control , Atención Prenatal/normas
4.
Am J Perinatol ; 38(3): 212-217, 2021 02.
Artículo en Inglés | MEDLINE | ID: mdl-32791538

RESUMEN

OBJECTIVE: This study aimed to examine the rates of intraamniotic infection between intrauterine pressure catheter with amnioinfusion and intrauterine pressure catheter alone. STUDY DESIGN: This was a retrospective cohort study of all women who had an intrauterine pressure catheter placement during labor at a tertiary referral hospital from January 2016 to June 2018. Outcomes were compared between women who had an intrauterine pressure catheter with amnioinfusion and intrauterine pressure catheter placement alone. The primary outcome was the rate of intraamniotic infection. Secondary outcomes included postpartum endometritis, postpartum hemorrhage (blood loss of ≥1,000 mL), quantitative blood loss (mL), and cesarean delivery. Multivariable logistic regression analysis was performed to calculate adjusted odds ratios (aOR) and 95% confidence interval (95% CI), controlling for age, race, body mass index, gestational age, and length of time of rupture of membranes. RESULTS: Of 1,268 women with an intrauterine pressure catheter, 298 (23.5%) also had an amnioinfusion. Women who had amnioinfusion through an intrauterine pressure catheter compared with those who had intrauterine pressure catheter alone had similar rates of intraamniotic infection (5.4 vs. 8.0%, crude p = 0.12, aOR 0.69; 95% CI 0.39-1.21), as well as secondary outcomes such as postpartum endometritis (3.0 vs. 2.5%, crude p = 0.61, aOR 1.12; 95% CI 0.49-2.53), postpartum hemorrhage (16.1 vs. 15.8%, crude p = 0.89, aOR 1.07; 95% CI 0.75-1.54), blood loss (479.5 vs. 500 mL, adjusted p = 0.89), and cesarean delivery (40.6 vs. 43.1%, crude p = 0.45, aOR 0.90; 95% CI 0.68-1.19). CONCLUSION: Amnioinfusion was not associated with increased odds of intraamniotic infection compared with intrauterine pressure catheter placement alone. KEY POINTS: · Amnioinfusion involves instilling fluid into the amniotic cavity to relieve variable decelerations.. · Amnioinfusion is not associated with increased odds of chorioamnionitis compared to IUPC alone.. · Amnioinfusion is not associated with increased odds of PPH compared to IUPC placement alone..


Asunto(s)
Líquido Amniótico , Catéteres , Corioamnionitis/terapia , Adulto , Cuello del Útero , Cesárea/estadística & datos numéricos , Endometritis/epidemiología , Femenino , Edad Gestacional , Humanos , Infecciones/epidemiología , Modelos Logísticos , Análisis Multivariante , Hemorragia Posparto/epidemiología , Embarazo , Estudios Retrospectivos , Centros de Atención Terciaria , Adulto Joven
5.
MULTIMED ; 24(6)2020.
Artículo en Español | CUMED | ID: cum-78235

RESUMEN

Introducción: se realiza una revisión bibliográfica sobre la repercusión de la corioamnionitis como factor de riesgo en la sepsis neonatal temprana para la madre y el neonato en el Hospital Provincial Universitario Docente Carlos Manuel de Céspedes en Bayamo, Granma en los cinco primeros meses del año 2019. Objetivo: profundizar el conocimiento de este factor de riesgo, su etiopatogenia, factores predisponentes, diagnóstico clínico y de laboratorio, riesgos para la madre y repercusión en el recién nacido, su prevención y tratamiento. Métodos: se utilizaron libros de texto específicos de Medicina y se realizó la recopilación de artículos de Internet a través de buscadores como el Servicio de la Editorial Elsevier, Secretaría de Ciencia y Técnica de la Nación, LILACS, MEDLINE con la asistencia del buscador específico PUBMED, IMBIOMED, La Biblioteca Cochrane, SciELO. Resultados: su incidencia en los partos pretérmino es mayor que en las gestaciones a término. Representa una de las tres principales causas de infección antes de término del embarazo con membranas íntegras y en caso de rotura prematura de membranas. Conclusiones: la repercusión en la madre incluye el parto pretérmino, si cesárea (atonía uterina o hemorragia postparto, absceso pélvico, tromboembolismo y endometritis, sepsis puerperal y la infección del torrente sanguíneo, mientras que en el neonato la leucomalacia periventricular con la consiguiente hemorragia periventricular, la broncodisplasia pulmonar, enterocolitis necrotizante, parálisis cerebral y el retraso mental(AU)


Introduction: a bibliographical review on the impact of Chorioamnionitis as a risk factor in early neonatal sepsis for the mother and the newborn in the Provincial University Hospital Carlos Manuel de Céspedes is carried out in Bayamo, Granma in the first five months of the year 2019. Objective: to deepen the knowledge of this risk factor, its pathogenesis, predisposing factors, clinical and laboratory diagnosis, risks to the mother and repercussion in the newborn, its prevention and treatment. Methods: medicine-specific textbooks were used and the collection of Internet articles was made through search engines such as the service of the Editorial Elsevier, Secretariat of Science and Technology of the nation, LILACS, MEDLINE with the assistance of Specific search engine PUBMED, imbiomed, the Cochrane Library, SciELO. Results: its incidence in preterm births is greater than in term gestations. It represents one of the three main causes of infection before the end of pregnancy with intact membranes and in case of premature rupture of membranes. Conclusion: the impact on the mother includes preterm delivery, if caesarean section (uterine sluggishness or postpartum hemorrhage, pelvic abscess, thromboembolism and endometritis, puerperal sepsis and blood stream infection, while in the neonate the Periventricular periventricular with consequent periventricular hemorrhage, pulmonary broncodisplasia, necrotizing enterocolitis, cerebral palsy and mental retardation(EU)


Asunto(s)
Humanos , Recién Nacido , Complicaciones Infecciosas del Embarazo/prevención & control , Sepsis Neonatal/prevención & control , Corioamnionitis/diagnóstico , Corioamnionitis/terapia , Factores de Riesgo , Ultrasonografía/métodos
6.
Semin Fetal Neonatal Med ; 25(4): 101146, 2020 08.
Artículo en Inglés | MEDLINE | ID: mdl-33164775

RESUMEN

The fetus can deploy a local or systemic inflammatory response when exposed to microorganisms or, alternatively, to non-infection-related stimuli (e.g., danger signals or alarmins). The term "Fetal Inflammatory Response Syndrome" (FIRS) was coined to describe a condition characterized by evidence of a systemic inflammatory response, frequently a result of the activation of the innate limb of the immune response. FIRS can be diagnosed by an increased concentration of umbilical cord plasma or serum acute phase reactants such as C-reactive protein or cytokines (e.g., interleukin-6). Pathologic evidence of a systemic fetal inflammatory response indicates the presence of funisitis or chorionic vasculitis. FIRS was first described in patients at risk for intraamniotic infection who presented preterm labor with intact membranes or preterm prelabor rupture of the membranes. However, FIRS can also be observed in patients with sterile intra-amniotic inflammation, alloimmunization (e.g., Rh disease), and active autoimmune disorders. Neonates born with FIRS have a higher rate of complications, such as early-onset neonatal sepsis, intraventricular hemorrhage, periventricular leukomalacia, and death, than those born without FIRS. Survivors are at risk for long-term sequelae that may include bronchopulmonary dysplasia, neurodevelopmental disorders, such as cerebral palsy, retinopathy of prematurity, and sensorineuronal hearing loss. Experimental FIRS can be induced by intra-amniotic administration of bacteria, microbial products (such as endotoxin), or inflammatory cytokines (such as interleukin-1), and animal models have provided important insights about the mechanisms responsible for multiple organ involvement and dysfunction. A systemic fetal inflammatory response is thought to be adaptive, but, on occasion, may become dysregulated whereby a fetal cytokine storm ensues and can lead to multiple organ dysfunction and even fetal death if delivery does not occur ("rescued by birth"). Thus, the onset of preterm labor in this context can be considered to have survival value. The evidence so far suggests that FIRS may compound the effects of immaturity and neonatal inflammation, thus increasing the risk of neonatal complications and long-term morbidity. Modulation of a dysregulated fetal inflammatory response by the administration of antimicrobial agents, anti-inflammatory agents, or cell-based therapy holds promise to reduce infant morbidity and mortality.


Asunto(s)
Corioamnionitis/inmunología , Corioamnionitis/fisiopatología , Trabajo de Parto Prematuro/fisiopatología , Síndrome de Respuesta Inflamatoria Sistémica/inmunología , Síndrome de Respuesta Inflamatoria Sistémica/fisiopatología , Adulto , Corioamnionitis/diagnóstico , Corioamnionitis/terapia , Citocinas/sangre , Femenino , Feto , Humanos , Recién Nacido , Enfermedades del Prematuro/inmunología , Enfermedades del Prematuro/fisiopatología , Interleucina-6/sangre , Embarazo , Síndrome de Respuesta Inflamatoria Sistémica/diagnóstico
7.
Am J Obstet Gynecol ; 223(6): 848-869, 2020 12.
Artículo en Inglés | MEDLINE | ID: mdl-33007269

RESUMEN

This review aimed to examine the existing evidence about interventions proposed for the treatment of clinical chorioamnionitis, with the goal of developing an evidence-based contemporary approach for the management of this condition. Most trials that assessed the use of antibiotics in clinical chorioamnionitis included patients with a gestational age of ≥34 weeks and in labor. The first-line antimicrobial regimen for the treatment of clinical chorioamnionitis is ampicillin combined with gentamicin, which should be initiated during the intrapartum period. In the event of a cesarean delivery, patients should receive clindamycin at the time of umbilical cord clamping. The administration of additional antibiotic therapy does not appear to be necessary after vaginal or cesarean delivery. However, if postdelivery antibiotics are prescribed, there is support for the administration of an additional dose. Patients can receive antipyretic agents, mainly acetaminophen, even though there is no clear evidence of their benefits. Current evidence suggests that the administration of antenatal corticosteroids for fetal lung maturation and of magnesium sulfate for fetal neuroprotection to patients with clinical chorioamnionitis between 24 0/7 and 33 6/7 weeks of gestation, and possibly between 23 0/7 and 23 6/7 weeks of gestation, has an overall beneficial effect on the infant. However, delivery should not be delayed to complete the full course of corticosteroids and magnesium sulfate. Once the diagnosis of clinical chorioamnionitis has been established, delivery should be considered, regardless of the gestational age. Vaginal delivery is the safer option and cesarean delivery should be reserved for standard obstetrical indications. The time interval between the diagnosis of clinical chorioamnionitis and delivery is not related to most adverse maternal and neonatal outcomes. Patients may require a higher dose of oxytocin to achieve adequate uterine activity or greater uterine activity to effect a given change in cervical dilation. The benefit of using continuous electronic fetal heart rate monitoring in these patients is unclear. We identified the following promising interventions for the management of clinical chorioamnionitis: (1) an antibiotic regimen including ceftriaxone, clarithromycin, and metronidazole that provides coverage against the most commonly identified microorganisms in patients with clinical chorioamnionitis; (2) vaginal cleansing with antiseptic solutions before cesarean delivery with the aim of decreasing the risk of endometritis and, possibly, postoperative wound infection; and (3) antenatal administration of N-acetylcysteine, an antioxidant and antiinflammatory agent, to reduce neonatal morbidity and mortality. Well-powered randomized controlled trials are needed to assess these interventions in patients with clinical chorioamnionitis.


Asunto(s)
Antibacterianos/uso terapéutico , Cesárea/métodos , Corioamnionitis/terapia , Parto Obstétrico/métodos , Edad Gestacional , Acetilcisteína/uso terapéutico , Corticoesteroides/uso terapéutico , Ampicilina/uso terapéutico , Antiinfecciosos Locales/uso terapéutico , Antioxidantes/uso terapéutico , Antipiréticos/uso terapéutico , Ceftriaxona/uso terapéutico , Claritromicina/uso terapéutico , Clindamicina/uso terapéutico , Endometritis/prevención & control , Medicina Basada en la Evidencia , Femenino , Gentamicinas/uso terapéutico , Humanos , Sulfato de Magnesio/uso terapéutico , Metronidazol/uso terapéutico , Guías de Práctica Clínica como Asunto , Embarazo , Infección Puerperal/prevención & control , Tocolíticos/uso terapéutico
8.
Semin Perinatol ; 44(5): 151270, 2020 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-32624201

RESUMEN

Some complications of pregnancy that occur in the second trimester, such as preeclampsia, bleeding placenta previa, and preterm premature rupture of membranes, require delivery to avoid maternal morbidity and mortality. When these situations occur before fetal viability, pregnancy termination, either by induction of labor or dilation and evacuation, can be lifesaving. To optimize maternal health in these situations, Maternal Fetal Medicine providers should be trained to provide all needed medical services, including termination. Currently, only the minority of Maternal Fetal Medicine providers are skilled in dilation and evacuation. Training programs should focus on ways to facilitate training in second trimester dilation and evacuation to improve care access and quality when these medically necessary procedures are needed for women in whom a healthy pregnancy is no longer an option.


Asunto(s)
Aborto Terapéutico/métodos , Placenta Previa/terapia , Preeclampsia/terapia , Servicios de Salud Reproductiva , Hemorragia Uterina/terapia , Aborto Inducido/educación , Aborto Inducido/métodos , Aborto Terapéutico/educación , Desprendimiento Prematuro de la Placenta/terapia , Corioamnionitis/terapia , Competencia Clínica , Anomalías Congénitas , Femenino , Rotura Prematura de Membranas Fetales/terapia , Viabilidad Fetal , Humanos , Trabajo de Parto Inducido , Prioridad del Paciente , Perinatología/educación , Embarazo , Segundo Trimestre del Embarazo , Índice de Severidad de la Enfermedad
9.
Pediatr Neonatol ; 61(4): 371-377, 2020 08.
Artículo en Inglés | MEDLINE | ID: mdl-32201157

RESUMEN

Despite advances in neonatal intensive care in the recent decade, a large number of very preterm infants (VPIs) remain at risk for significant neurodevelopmental impairment (NDI). Given that there are many interventions need to be implemented during the critical perinatal period so that complications of these vulnerable VPIs could be minimized, it is urgent to develop multi-discipline strategies based on evidence to be carried out. The objective of this new term evidence-based perinatal critical strategies (EBPCS), is to provide beneficial intervention towards better neurodevelopmental outcomes, specifically for preterm infants below 28 weeks gestational age. EBPCS is defined as the management of the VPIs during the perinatal period which would include antenatal counseling with team briefing and share decision making, treat the chorioamnionitis, antenatal MgS04, antenatal steroid, delayed cord clamping/milking, neonatal resuscitation team preparation, prevention of hypothermia, immediate respiratory support with continuous positive airway pressure at delivery room, less invasive surfactant administration, early surfactant with budesonide therapy, support of cardiovascular system, early initiate of probiotics administration, early caffeine, early parenteral and enteral nutrition, promptly initiating antibiotics. These critical strategies will be discussed detail in the text; nonetheless, standardized protocols, technical skills and repeated training are the cornerstones of successful of EBPCS. Further experience from different NICU is needed to prove whether these very complicate and comprehensive perinatal critical strategies could translate into daily practice to mitigate the incidence of NDI in high-risk VPIs.


Asunto(s)
Recien Nacido Extremadamente Prematuro , Trastornos del Neurodesarrollo/prevención & control , Antibacterianos/uso terapéutico , Displasia Broncopulmonar/prevención & control , Budesonida/uso terapéutico , Cafeína/uso terapéutico , Estimulantes del Sistema Nervioso Central/uso terapéutico , Corioamnionitis/terapia , Presión de las Vías Aéreas Positiva Contínua , Consejo , Toma de Decisiones Conjunta , Nutrición Enteral , Práctica Clínica Basada en la Evidencia , Femenino , Glucocorticoides/uso terapéutico , Humanos , Hipotensión/prevención & control , Hipotermia/prevención & control , Lactante , Recién Nacido , Sulfato de Magnesio/uso terapéutico , Nutrición Parenteral , Grupo de Atención al Paciente , Embarazo , Nacimiento Prematuro/prevención & control , Atención Prenatal , Probióticos/uso terapéutico , Surfactantes Pulmonares/administración & dosificación , Resucitación , Tocolíticos/uso terapéutico
10.
Aliment Pharmacol Ther ; 51(3): 320-333, 2020 02.
Artículo en Inglés | MEDLINE | ID: mdl-31912546

RESUMEN

BACKGROUND: The effect of inflammatory bowel disease (IBD) on pregnancy-related outcomes remains unknown. AIM: To determine the risk of adverse maternal, placental and obstetric outcomes in IBD METHODS: We searched Medline, Embase and Cochrane library through May 2019 for studies reporting adverse maternal, placental and obstetric outcomes in patients with IBD. Odds ratios (OR) with 95% confidence intervals (CI) were calculated for these outcomes in patients with IBD compared to healthy controls. RESULTS: Fifty-three studies were included (7917 IBD pregnancies and 3253 healthy control pregnancies). Caesarean delivery was more common in patients with IBD compared to healthy controls (OR 1.79, 95% CI, 1.16-2.77). This remained significant for UC (OR 1.80, 95% CI, 1.21-2.90) but not CD (OR 1.48, 95% CI, 0.94-2.34). Similarly, gestational diabetes occurred more commonly in IBD (OR 2.96, 95% CI, 1.47-5.98). The incidences of placental diseases were 2.0% (95% CI, 0.9%-3.1%) for pre-eclampsia, 3.3% (95% CI, 0%-7.2%) for placental abruption, 0.5% (95% CI, 0.2%-0.9%) for placenta previa and 0.3% (95% CI, 0%-0.5%) for chorioamnionitis. Patients with IBD were more likely to experience preterm prelabour rupture of membranes (OR 12.10, 95% CI, 2.15-67.98), but not early pregnancy loss (OR 1.63, 95% CI 0.49-5.43). Anti-tumour necrosis factor therapy was not associated with chorioamnionitis (OR 1.12, 95% CI, 0.16-7.67), early pregnancy loss (OR 1.49, 95% CI, 0.83-2.64) or placenta previa (OR 1.58, 95% CI, 0.30-8.47). CONCLUSIONS: Gestational diabetes and preterm prelabour rupture of membranes occurs more commonly in patients with IBD, although the incidence of placental diseases remains low.


Asunto(s)
Enfermedades Inflamatorias del Intestino/diagnóstico , Enfermedades Inflamatorias del Intestino/epidemiología , Complicaciones del Embarazo/diagnóstico , Complicaciones del Embarazo/epidemiología , Resultado del Embarazo/epidemiología , Corioamnionitis/epidemiología , Corioamnionitis/terapia , Parto Obstétrico/métodos , Parto Obstétrico/estadística & datos numéricos , Femenino , Humanos , Recién Nacido , Enfermedades Inflamatorias del Intestino/complicaciones , Enfermedades Inflamatorias del Intestino/terapia , Enfermedades Placentarias/epidemiología , Enfermedades Placentarias/terapia , Embarazo , Complicaciones del Embarazo/terapia , Pronóstico , Factores de Riesgo
12.
Hosp Pediatr ; 9(4): 227-233, 2019 04.
Artículo en Inglés | MEDLINE | ID: mdl-30833294

RESUMEN

BACKGROUND: Antibiotic use in well-appearing late preterm and term chorioamnionitis-exposed (CE) infants was reduced by 88% after the adoption of a care approach that was focused on clinical monitoring in the intensive care nursery to determine the need for antibiotics. However, this approach continued to separate mothers and infants. We aimed to reduce maternal-infant separation while continuing to use a clinical examination-based approach to identify early-onset sepsis (EOS) in CE infants. METHODS: Within a quality improvement framework, well-appearing CE infants ≥35 weeks' gestation were monitored clinically while in couplet care in the postpartum unit without laboratory testing or empirical antibiotics. Clinical monitoring included physician examination at birth and nurse examinations every 30 minutes for 2 hours and then every 4 hours until 24 hours of life. Infants who developed clinical signs of illness were further evaluated and/or treated with antibiotics. Antibiotic use, laboratory testing, and clinical outcomes were collected. RESULTS: Among 319 initially well-appearing CE infants, 15 (4.7%) received antibiotics, 23 (7.2%) underwent laboratory testing, and 295 (92.5%) remained with their mothers in couplet care throughout the birth hospitalization. One infant had group B Streptococcus EOS identified and treated at 24 hours of age based on new-onset tachypnea and had an uncomplicated course. CONCLUSIONS: Management of well-appearing CE infants by using a clinical examination-based approach during couplet care in the postpartum unit maintained low rates of laboratory testing and antibiotic use and markedly reduced mother-infant separation without adverse events. A framework for repeated clinical assessments is an essential component of identifying infants with EOS.


Asunto(s)
Antibacterianos/uso terapéutico , Corioamnionitis/tratamiento farmacológico , Cuidado del Lactante/métodos , Recien Nacido Prematuro , Periodo Posparto , Corioamnionitis/terapia , Manejo de la Enfermedad , Femenino , Humanos , Recién Nacido , Unidades de Cuidado Intensivo Neonatal , Masculino , Relaciones Madre-Hijo , Embarazo
13.
J Perinat Med ; 47(5): 493-499, 2019 Jul 26.
Artículo en Inglés | MEDLINE | ID: mdl-30817305

RESUMEN

Objective To assess the value of incorporating amniotic fluid (AF) analysis in the management of patients with clinical chorioamnionitis. Methods This was a retrospective cohort study of all women carrying a singleton fetus and managed at our center between 2000 and 2009. We included only those women suspected of chorioamnionitis based on one or more of the following: (1) uterine tenderness, (2) maternal fever, (3) maternal and/or fetal tachycardia and (4) purulent discharge. The management was deemed to be justified if (1) pregnancy was terminated <24 weeks and histology confirmed chorioamnionitis; (2) delivery was performed expeditiously after initial assessment and histology confirmed chorioamnionitis; (3) delivery was delayed for 2-7 days and the patient completed a course of antenatal steroids before 34 weeks; and (4) delivery was delayed ≥7 days and histology was not indicative of chorioamnionitis, or delivery occurred after 37 weeks. Univariate and logistic regression analyses were used as appropriate. Results Of the 77 women with suspected chorioamnionitis, AF analysis was performed in 43 (55.8%) cases, and the management was justified in 63 (81.8%) cases based on the aforementioned criteria. Stepwise regression analysis confirmed AF analysis as a predictor of justified management. The rates of composite morbidity, neonatal sepsis, neonatal death and admissions to neonatal intensive care unit were lower in the justified management group. Conclusion Incorporation of AF analysis into clinical assessment does improve the management of suspected chorioamnionitis.


Asunto(s)
Líquido Amniótico/química , Corioamnionitis/diagnóstico , Corioamnionitis/terapia , Femenino , Humanos , Lactante , Mortalidad Infantil , Recién Nacido , Embarazo , Estudios Retrospectivos
14.
J Matern Fetal Neonatal Med ; 32(2): 271-278, 2019 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-28936902

RESUMEN

OBJECTIVE: To determine the association between maternal obesity and delivery due to chorioamnionitis prior to labor onset, among expectantly managed women with preterm premature rupture of membranes (pPROM). METHODS: This was a secondary analysis of a multicenter randomized trial of magnesium sulfate versus placebo to prevent cerebral palsy or death among offspring of women with anticipated delivery at 24-31-week gestation. After univariable analysis, Cox proportional hazard evaluated the association between maternal obesity and chorioamnionitis, while Laplace regression investigated how obesity affects the gestational age at delivery of the first 20% of women developing the outcome of interest. RESULTS: A total of 164 of the 1942 women with pPROM developed chorioamnionitis prior to labor onset. Obese women had a 60% increased hazard of developing such complication (adjusted HR 1.6, 95%CI 1.1-2.1, p = .008), prompting delivery 1.5 weeks earlier, as the 20th survival percentile was 27.2-week gestation (95%CI 26-28.6) among obese as opposed to 28.8 weeks (95%CI 27.4-30.1) (p = .002) among nonobese women. CONCLUSIONS: Maternal obesity is a risk factor for chorioamnionitis prior to labor onset. Future studies will determine if obesity is important enough to change the management of latency after pPROM according to maternal BMI.


Asunto(s)
Corioamnionitis/epidemiología , Rotura Prematura de Membranas Fetales/epidemiología , Rotura Prematura de Membranas Fetales/terapia , Obesidad/epidemiología , Complicaciones del Embarazo/epidemiología , Nacimiento Prematuro/epidemiología , Adulto , Cesárea/estadística & datos numéricos , Corioamnionitis/terapia , Femenino , Humanos , Recién Nacido , Sulfato de Magnesio/uso terapéutico , Obesidad/complicaciones , Obesidad/terapia , Embarazo , Complicaciones del Embarazo/terapia , Resultado del Embarazo/epidemiología , Nacimiento Prematuro/terapia , Estudios Retrospectivos , Factores de Tiempo
15.
BJOG ; 126(6): 719-727, 2019 May.
Artículo en Inglés | MEDLINE | ID: mdl-30485648

RESUMEN

OBJECTIVE: To investigate the association of chorioamnionitis and its duration with adverse maternal outcomes by mode of delivery. DESIGN: A retrospective cohort study. SETTING: Data from the Consortium on Safe Labor Study in the USA (2002-2008). POPULATION: Singleton deliveries at ≥23 weeks of gestation (221 274 assessed deliveries, 62 331 by caesarean section). METHODS: The association of chorioamnionitis, and secondarily the duration of chorioamnionitis estimated from intrapartum antibiotic use, with adverse maternal outcomes was analysed using logistic regression with generalised estimating equations, adjusting for age, parity, race, pregestational diabetes, chronic hypertension, gestational age at delivery, study site and delivery year. Analyses were stratified by vaginal versus caesarean delivery. MAIN OUTCOME MEASURES: The composite adverse maternal outcome included: postpartum transfusion, endometritis, wound/perineal infection/separation, venous thromboembolism, hysterectomy, admission to intensive care unit and/or death. RESULTS: Chorioamnionitis was associated with higher odds of the composite adverse maternal outcome with caesarean delivery (adjusted odds ratio 2.31; 95% CI 1.97-2.71); and the association persisted regardless of whether a woman had a trial of labour, preterm delivery or maternal group B streptococcus colonisation. The most common adverse outcomes after caesarean section were postpartum transfusion (56.0%) and wound/perineal infection or endometritis (38.6%). Chorioamnionitis was not associated with adverse maternal outcomes after vaginal delivery. The duration of chorioamnionitis as the exposure did not alter the association between chorioamnionitis and adverse maternal outcomes. CONCLUSIONS: Chorioamnionitis, but not the estimated duration, was associated with increased odds of adverse maternal outcomes with caesarean delivery. This finding has implications for care programmes to prevent maternal morbidity after a caesarean section complicated by chorioamnionitis. TWEETABLE ABSTRACT: Chorioamnionitis, but not its duration, increases the risk of adverse maternal outcomes with caesarean delivery.


Asunto(s)
Cesárea , Corioamnionitis , Parto Obstétrico , Complicaciones del Trabajo de Parto/epidemiología , Adulto , Antibacterianos/uso terapéutico , Cesárea/efectos adversos , Cesárea/estadística & datos numéricos , Corioamnionitis/diagnóstico , Corioamnionitis/epidemiología , Corioamnionitis/terapia , Parto Obstétrico/efectos adversos , Parto Obstétrico/métodos , Parto Obstétrico/estadística & datos numéricos , Femenino , Edad Gestacional , Humanos , Recién Nacido , Trabajo de Parto/fisiología , Embarazo , Complicaciones del Embarazo/diagnóstico , Complicaciones del Embarazo/epidemiología , Resultado del Embarazo/epidemiología , Factores de Tiempo , Estados Unidos/epidemiología
16.
Dev Neurosci ; 40(3): 258-270, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-30179864

RESUMEN

BACKGROUND: Infants born preterm following exposure to in utero inflammation/chorioamnionitis are at high risk of brain injury and life-long neurological deficits. In this study, we assessed the efficacy of early intervention umbilical cord blood (UCB) cell therapy in a large animal model of preterm brain inflammation and injury. We hypothesised that UCB treatment would be neuroprotective for the preterm brain following subclinical fetal inflammation. METHODS: Chronically instrumented fetal sheep at 0.65 gestation were administered lipopolysaccharide (LPS, 150 ng, 055:B5) intravenously over 3 consecutive days, followed by 100 million human UCB mononuclear cells 6 h after the final LPS dose. Controls were administered saline instead of LPS and cells. Ten days after the first LPS dose, the fetal brain and cerebrospinal fluid were collected for analysis of subcortical and periventricular white matter injury and inflammation. RESULTS: LPS administration increased microglial aggregate size, neutrophil recruitment, astrogliosis and cell death compared with controls. LPS also reduced total oligodendrocyte count and decreased mature myelinating oligodendrocytes. UCB cell therapy attenuated cell death and inflammation, and recovered total and mature oligodendrocytes, compared with LPS. CONCLUSIONS: UCB cell treatment following inflammation reduces preterm white matter brain injury, likely mediated via anti-inflammatory actions.


Asunto(s)
Lesiones Encefálicas/terapia , Encefalitis/terapia , Sangre Fetal/citología , Lipopolisacáridos/farmacología , Animales , Corioamnionitis/terapia , Modelos Animales de Enfermedad , Femenino , Feto/citología , Humanos , Microglía/citología , Embarazo , Ovinos , Sustancia Blanca/efectos de los fármacos
17.
Eur J Obstet Gynecol Reprod Biol ; 222: 134-141, 2018 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-29408744

RESUMEN

Preterm birth, defined as birth occurring prior to 37 weeks gestation is a common obstetric complication affecting 8% of pregnancies and is associated with significant morbidity and mortality. Infection/inflammation has been implicated in both the aetiology of preterm birth itself and associated neonatal pulmonary and neurological morbidity. Treatment options are currently limited to prolongation of the pregnancy using cervical cerclage, pessaries or progesterone or administration of drugs including steroids to promote lung maturity and neuroprotective agents such as magnesium sulphate, the timing of which are highly critical. Although delivery is expedited in cases of overt infection, decisions regarding timing and mode of delivery in subclinical infection are not clear-cut. This review aims to explore the use of magnetic resonance imaging (MRI) in the antenatal assessment of pregnancies at high risk of preterm birth and its potential to guide management decisions in the future.


Asunto(s)
Rotura Prematura de Membranas Fetales/diagnóstico por imagen , Embarazo de Alto Riesgo , Nacimiento Prematuro/prevención & control , Diagnóstico Prenatal , Líquido Amniótico/diagnóstico por imagen , Líquido Amniótico/inmunología , Líquido Amniótico/microbiología , Corioamnionitis/diagnóstico por imagen , Corioamnionitis/etiología , Corioamnionitis/fisiopatología , Corioamnionitis/terapia , Femenino , Desarrollo Fetal , Rotura Prematura de Membranas Fetales/microbiología , Rotura Prematura de Membranas Fetales/fisiopatología , Rotura Prematura de Membranas Fetales/terapia , Humanos , Imagen por Resonancia Magnética , Oligohidramnios/diagnóstico por imagen , Oligohidramnios/etiología , Oligohidramnios/fisiopatología , Oligohidramnios/terapia , Guías de Práctica Clínica como Asunto , Embarazo , Complicaciones Infecciosas del Embarazo/diagnóstico por imagen , Complicaciones Infecciosas del Embarazo/etiología , Complicaciones Infecciosas del Embarazo/fisiopatología , Complicaciones Infecciosas del Embarazo/terapia , Nacimiento Prematuro/epidemiología , Nacimiento Prematuro/etiología , Riesgo
18.
Issues Law Med ; 33(2): 247-256, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-30831015

RESUMEN

When intrauterine infection develops prior to viability, prognosis for the fetus is guarded. Previable partuition can be pursued when infection is present, but physician must challenge themselves to do only what is indicated and avoid causing unnecessary effects by their methods of terminating pregnancy.


Asunto(s)
Corioamnionitis , Trabajo de Parto Inducido , Trabajo de Parto Prematuro , Corioamnionitis/terapia , Femenino , Feto , Humanos , Trabajo de Parto , Embarazo
20.
Pediatr Neonatol ; 59(3): 231-237, 2018 06.
Artículo en Inglés | MEDLINE | ID: mdl-29066072

RESUMEN

Chorioamnionitis is a common cause of preterm birth and may cause adverse neonatal outcomes, including neurodevelopmental sequelae. Chorioamnionitis has been marked to a heterogeneous setting of conditions characterized by infection or inflammation or both, followed by a great variety in clinical practice for mothers and their newborns. Recently, a descriptive term: "intrauterine inflammation or infection or both" abbreviated as "Triple I" has been proposed by a National Institute of Child Health and Human Development expert panel to replace the term chorioamnionitis. It is particularly important to recognize that an isolated maternal fever does not automatically equate to chorioamnionitis. This article will review the current literature on chorioamnionitis, and introduce the concept of Triple I, as well as recommendations for assessment and management of pregnant women and their newborns with a diagnosis of Triple I.


Asunto(s)
Corioamnionitis/terapia , Infecciones/terapia , Inflamación/terapia , Biomarcadores , Corioamnionitis/diagnóstico , Femenino , Humanos , Recién Nacido , Infecciones/diagnóstico , Inflamación/diagnóstico , Embarazo , Nacimiento Prematuro/etiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...